Patients with APL carrying the promyelocytic leukemia-retinoic acid receptor alpha (PML::RARA) fusion gene caused by the chromosomal translocation t(15;17)(q22;q21) are sensitive to ATRA and ATO treatments (1). This evidence concerns the gene RARA and acute promyelocytic leukemia.